| 08/03 | Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating | MT |
| 08/03 | Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra.. | MT |
| 08/03 | Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin.. | MT |
| 08/02 | TRANSCRIPT : Sage Therapeutics, Inc., Q2 2022 Earnings Call, Aug 02, 2022 | CI |
| 08/02 | Sage Therapeutics Widens Q2 Net Loss as Revenue Declines | MT |
| 08/02 | SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 08/02 | Sage Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months .. | CI |
| 08/02 | SAGE THERAPEUTICS : Announces Second Quarter 2022 Financial Results and Highlights Pipelin.. | PU |
| 08/02 | Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeli.. | BU |
| 08/01 | Sage Therapeutics to Present at Upcoming August Investor Conferences | BU |
| 07/19 | Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2,.. | BU |
| 07/14 | SAGE THERAPEUTICS : IF YOU DO NOT OBJECT TO THE PROPOSED SETTLEMENT, OR THE AGREED-TO ATTO.. | PU |
| 07/14 | SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 07/11 | SVB Securities Adjusts Sage Therapeutics' Price Target to $40 from $50, Keeps Market Pe.. | MT |
| 07/01 | Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcar.. | MT |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) dropped from Russell 1000 Dynamic Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) added to Russell 2000 Dynamic Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) added to Russell 2000 Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) dropped from Russell Midcap Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) dropped from Russell 1000 Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) added to Russell 2000 Value Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) dropped from Russell 1000 Value Index | CI |
| 06/24 | SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) dropped from Russell Midcap Value Index | CI |
| 06/21 | SAGE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters.. | AQ |
| 06/13 | TRANSCRIPT : Sage Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthca.. | CI |
| 06/13 | SAGE THERAPEUTICS, INC. : Other Events (form 8-K) | AQ |
| 06/13 | Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update | CI |
| 06/08 | TRANSCRIPT : Sage Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conferen.. | CI |
| 06/02 | RBC Capital Adjusts Price Target for Sage Therapeutics to $37 From $35, Maintains Secto.. | MT |
| 06/02 | Sage Therapeutics to Present at Upcoming June Investor Conferences | BU |
| 06/01 | WALL STREET STOCK EXCHANGE : Wall Street starts a new chapter | |
| 06/01 | TRANSCRIPT : Sage Therapeutics, Inc. - Special Call | CI |
| 06/01 | SAGE THERAPEUTICS : and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Po.. | PU |
| 06/01 | SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 06/01 | Sage Therapeutics, Biogen Say Phase 3 Study of Postpartum Depression Treatment Met Prim.. | MT |
| 06/01 | Sage-Biogen drug improves symptoms in postpartum depression study | RE |
| 06/01 | Sage, Biogen's drug meets main goal in postpartum depression study | RE |
| 06/01 | Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in P.. | BU |
| 06/01 | SAGE, BIOGEN : Zuranolone Hits Key Goals in Postpartum Depression | DJ |
| 05/24 | Goldman Sachs Lowers Sage Therapeutics' Price Target to $73 From $85, Maintains Buy Rat.. | MT |
| 05/11 | TRANSCRIPT : Sage Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conferenc.. | CI |
| 05/10 | Morgan Stanley Adjusts Sage Therapeutics' Price Target to $53 from $57, Keeps Equalweig.. | MT |
| 05/09 | INSIDER BUY : Sage Therapeutics | MT |
| 05/04 | Mizuho Securities Adjusts Sage Therapeutics' Price Target to $37 From $41, Maintains Ne.. | MT |
| 05/04 | RBC Cuts Price Target on Sage Therapeutics to $35 From $37, Citing Cash Burn Guidance, .. | MT |
| 05/04 | Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference | BU |
| 05/03 | Wedbush Lowers Price Target for Sage Therapeutics to $54 From $75, Maintains Outperform.. | MT |
| 05/03 | TRANSCRIPT : Sage Therapeutics, Inc., Q1 2022 Earnings Call, May 03, 2022 | CI |
| 05/03 | SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 05/03 | Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, .. | CI |
| 05/03 | Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipelin.. | BU |
| 05/03 | Sage Therapeutics Appoints Mark Pollack as Senior Vice President, Medical Affairs | CI |
| 05/02 | Sage, Biogen Start Rolling Submission of New-Drug Application to US FDA for Major Depre.. | MT |
| 05/02 | Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) .. | BU |
| 04/19 | Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 202.. | BU |
| 04/04 | CORRECTION : Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
| 04/04 | CORRECTION : Sector Update: Health Care | MT |
| 04/04 | CORRECTION : Sector Update: Health Care Stocks Finishing Near Friday Session Highs | MT |
| 04/04 | CORRECTION : Sage Therapeutics Reports 'Promising' Results in Study of Treatment for Mild .. | MT |
| 04/04 | Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY.. | AQ |
| 04/01 | SECTOR UPDATE : Health Care Stocks Finishing Near Friday Session Highs | MT |
| 04/01 | SECTOR UPDATE : Health Care | MT |
| 04/01 | SECTOR UPDATE : Health Care Stocks Advance Pre-Bell Friday | MT |
| 04/01 | Sage Therapeutics Reports 'Promising' Results in Study of Treatment for Mild Dementia D.. | MT |
| 04/01 | Wall Street Leans Forward Pre-Bell; Futures Green, Europe Up, Asia Choppy | MT |
| 04/01 | Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY.. | BU |
| 04/01 | Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary.. | CI |
| 03/31 | Berenberg Bank Initiates Sage Therapeutics at Hold With $37 Price Target | MT |
| 03/29 | TRANSCRIPT : Sage Therapeutics, Inc. Presents at Stifel CNS Days, Mar-29-2022 04:00 PM | CI |
| 03/22 | Sage Therapeutics to Present at 2022 Stifel CNS Days | BU |
| 03/15 | Sage Therapeutics' Treatment for Parkinson's-related Cognitive Deficit Improves Patient.. | MT |
| 03/15 | Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADI.. | BU |
| 03/10 | Morgan Stanley Adjusts Sage Therapeutics' Price Target to $57 from $61, Keeps Equalweig.. | MT |
| 03/07 | TRANSCRIPT : Sage Therapeutics, Inc. Presents at 42nd Annual Cowen Health Care Conference,.. | CI |
| 03/03 | Mizuho Securities Adjusts Sage Therapeutics' Price Target to $41 From $44, Maintains Ne.. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
